Biocon is a company that manufactures biotechnology goods and provides research services. With vertically integrated operations across APIs and intricate formulations, Biocon is a major player in the worldwide generics market. Biocon offers nephrology, immunotherapy, cancer, and metabolics formulations for the Indian market. Itolizumab, an anti-CD6 antibody introduced for psoriasis in India, is one of Biocon’s innovative biologics. The US-based affiliate Bicara Therapeutics uses developments in immuno-oncology to create bifunctional antibodies.
Biocon – Quick Overview
| Particular | Details |
| Company Name | Biocon Limited |
| Type | Public Listed Biopharmaceutical Company |
| Industry | Biopharmaceuticals & Biotechnology |
| Founded / Incorporated | 29 November 1978 |
| Founder | Kiran Mazumdar-Shaw |
| Headquarters | Bengaluru, Karnataka, India |
| Key People | Kiran Mazumdar-Shaw (Executive Chairperson); Siddharth Mittal (CEO & MD); Peter Bains (Group CEO) |
| Core Business | Research, development & manufacture of biopharmaceuticals, generic APIs, biosimilars & branded formulations |
| Major Products & Areas | Biosimilars (insulins, monoclonal antibodies), small molecules, generic APIs, oncology, diabetes & immunology products |
| Subsidiaries / Group Companies | Biocon Biologics, Syngene International |
| Global Presence | 120+ countries |
| Stock Exchange Listing | BSE & NSE |
| Employees | ~16,500+ (Mar 2023) |
| Notable Achievements | India’s first biosimilar approved in the U.S. & Japan; leader in affordable biologics |
| Strategic Focus | Innovation in biologics, biosimilars, chronic disease therapies |
| Official Website | biocon.com |
Net Worth and Market Cap
As of 2025, total assets increased by ₹58,797 crore (US$7.0 billion), while net income decreased by ₹1,013 crore (US$120 million).
Corporate leadership
With its headquarters located in Bridgewater, New Jersey, Biocon Limited is an Indian biopharmaceutical firm headquartered in Bengaluru. Kiran Mazumdar-Shaw started the business in 1978.
Overview of Services
Insulins, monoclonal antibodies, and conjugated recombinant proteins are among the 20 biosimilars that Biocon Biologics creates and sells for use in diabetes, cancer, immunology, ophthalmology, and other non-communicable illnesses. It is among the top three producers of insulin and one of the top five producers of biosimilars worldwide. It is present in more than 120 countries, including the United States, Europe, and emerging markets, and is among the top 15 corporations in the world for biomanufacturing capacity. Ten authorized biosimilars and ten in development are part of its product line.
Scale of Operations
In order to meet the demands of the global healthcare industry, its operations are organized across important business sectors, such as Novel Biologics, Biosimilars, Research and Manufacturing Services, and Generics. Biocon continues to make sure that life-saving medications are provided where they are most needed by utilizing cutting-edge science and establishing smart international partnerships. Through 78 new launches from its biosimilars and generics portfolio, the business successfully reached over 21 million patients in more than 120 countries in FY25.
The first Indian business to produce and ship enzymes to the US and Europe was Biocon. Syngene is an international CRDMO (Contract Research, Development, and Manufacturing Organization) that provides integrated services in the fields of animal health, biotech, pharmaceuticals, and nutrition.
Itolizumab, an anti-CD6 antibody introduced for psoriasis in India, is one of Biocon’s innovative biologics. The US-based affiliate Bicara Therapeutics uses developments in immuno-oncology to create bifunctional antibodies.
